Enlivex ENLV 深 滬
等待開盤 05-20 09:30:00 美东时间
0.7045
+0.007
+1.03%
華盛通- 最 高0.7152
- 今 開0.69
- 成交量 9.72万股
- 最 低 0.69
- 昨 收 0.6973
- 總市值 1.70亿
- 52周最高 2.10
- 市盈率 靜 0.03
- 換手率 0.04%
- 52周最低 0.66
- 委 比 95.12%
- 總股本 2.41亿
- 歷史最高 44.90
- 量 比 0.49
- 振 幅 3.61%
- 歷史最低 0.66
- 每 手 1
- 風險率 0.17%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多EnLivex Doses First Patient In Its Phase 2b Clinical Trial Of Allocetra For Treatment Of Patients With Moderate-to-Severe Age-Related Symptomatic Primary Knee Osteoarthritis
The global, multicenter, randomized, double-blind, placebo-controlled Phase 2b clinical trial is designed to evaluate the efficacy and safety of intra-articular injections of Allocetra™ in patients with
05-18 20:03
Enlivex receives Nasdaq non-compliance notice over sub-$1 share price
Enlivex(ENLV) was notified by Nasdaq that its share price stayed below the $1 minimum bid requirement for 30 consecutive business days. The company has until November 9, 2026, to regain compliance. I...
05-16 04:16
Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification
Enlivex Ltd. (Nasdaq: ENLV) received a notice from Nasdaq stating its ordinary shares closed below the $1.00 minimum bid price requirement over 30 consecutive business days. The company has 180 days until November 9, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. If unsuccessful, it may qualify for an additional 180-day period to demonstrate compliance. Failure to meet requirement...
05-15 20:10
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Psyence Biomedical (NASDAQ:PBM) shares increased by 63.4% to $9.59 dur...
04-17 05:05
美股大行评级 | 高盛首予PayPay“买入”评级；神经分泌生物科学获花旗等多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从13美元升至20美元；韦德布什：维持FuboTV"跑赢大市"评级，目标价从3.5美元升至24美元
04-08 18:35
HC Wainwright & Co. Maintains Buy on Enlivex, Raises Price Target to $20
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Enlivex (NASDAQ:ENLV) with a Buy and raises the price target from $13 to $20.
04-07 19:17
Enlivex Therapeutics Q4 EPS $26.83 Beats $(0.13) Estimate
Enlivex Therapeutics (NASDAQ:ENLV) reported quarterly earnings of $26.83 per share which beat the analyst consensus estimate of $(0.13) by 20738.46 percent. This is a 12295.45 percent increase over losses of $(0.22) per
03-25 20:39
Enlivex Receives First FDA Approval For Phase2b Trial Of Allocetra For Age-Related Osteoarthritis
The U.S. Food and Drug Administration (FDA) has cleared Enlivex's Investigational New Drug (IND) application for Allocetra, for the treatment of patients with moderate-to-severe age-related symptomatic primary knee
03-23 20:09
Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Enlivex获得FDA批准启动针对中重度与年龄相关的膝关节骨关节炎患者的2b期全球多中心临床试验。该试验将评估其免疫疗法Allocetra™的疗效与安全性。此前，1/2a期临床试验已显示显著治疗效果。Enlivex采用双引擎价值创造模式，结合质量寿命项目与预测市场 treasury 策略推动发展。 Knee osteoarthritis影响数千万美国人，亟需新疗法。Trial将评估疼痛、功能及生活质量指标，以验证Allocetra™的潜力。
03-23 12:00
